- Author:
Ben-Fa GONG
1
;
Ying WANG
2
;
Dong LIN
1
;
Hui WEI
1
;
Wei LI
1
;
Chun-Lin ZHOU
1
;
Bing-Cheng LIU
1
;
Kai-Qi LIU
1
;
Guang-Ji ZHANG
1
;
Yun-Tao LIU
1
;
Yan LI
1
;
Shu-Ning WEI
1
;
Xiao-Yuan GONG
1
;
Xing-Li ZHAO
1
;
Shao-Wei QIU
1
;
Run-Xia GU
1
;
Ying-Chang MI
1
;
Jian-Xiang WANG
1
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2016;24(6):1615-1621
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the influence of FLT3-ITD mutation on long term survival of newly diagnosed patients with acute promyelocytic leukemia (APL).
METHODSLong term survival of 170 newly diagnosed APL patients was retrospective analyzed. Mutation rate of FLT3-ITD was assayed, and its influence on disease-free survival(DFS) or overall survival (OS) was analyzed.
RESULTSThe mutation rate of FLT3-ITD in newly diagnosed patients with APL was 14.1%. WBC count at diagnosis was higer in FLT3-ITD positive group than that in negative group, and the mutation rate of FLT3-ITD was highest in high risk group. Induction death rate in FLT3-ITD positive and negative group were 12.5% and 2.9%, respectively (P=0.031). Complete remission(CR) rate in 2 groups were 83.3% and 97.1%(P=0.004). The 5-year OS rates in 2 groups were 87.5±6.8% and 90.6±2.6% (P=0.740). The 5-year DFS in 2 groups were 82.8±9.1% and 83.6±3.4%(P=0.928).
CONCLUSIONFLT3-ITD mutation is related with high peripheral white blood cell count in APL, the APL with FLT3-ITD mutation has higher induction death rate and lower CR rate than those in that without FLT3-ITD mutation, but FLT3-ITD mutation did not affect on long term DFS and OS.